1. Home
  2. AKA vs LUNG Comparison

AKA vs LUNG Comparison

Compare AKA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo a.k.a. Brands Holding Corp.

AKA

a.k.a. Brands Holding Corp.

N/A

Current Price

$9.27

Market Cap

113.4M

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.66

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKA
LUNG
Founded
2018
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
113.4M
57.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
AKA
LUNG
Price
$9.27
$1.66
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
$24.33
$5.38
AVG Volume (30 Days)
4.1K
501.7K
Earning Date
05-12-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
$600,208,000.00
$90,497,000.00
Revenue This Year
$6.14
$2.48
Revenue Next Year
$4.89
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
4.44
8.01
52 Week Low
$8.60
$1.13
52 Week High
$16.38
$3.88

Technical Indicators

Market Signals
Indicator
AKA
LUNG
Relative Strength Index (RSI) 38.78 68.55
Support Level $8.94 $1.51
Resistance Level $11.57 $1.93
Average True Range (ATR) 0.52 0.10
MACD -0.16 0.04
Stochastic Oscillator 6.35 89.90

Price Performance

Historical Comparison
AKA
LUNG

About AKA a.k.a. Brands Holding Corp.

a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: